Back to search results

Exercise for Black Prostate Cancer Patients on ADT

This study is looking at whether a 16-week exercise program can improve heart health in Black men with prostate cancer who are receiving androgen deprivation therapy (ADT). ADT is a treatment that lowers male hormones. The study will also look at how exercise affects physical fitness, body composition, quality of life, cancer symptoms, and self-esteem. You could be eligible if you are an adult Black man with localized or metastatic prostate cancer, are receiving ADT, and can travel to Dana-Farber Cancer Institute (DFCI). The study aims to see if the exercise program helps improve cardiovascular disease risk factors within 4 months.

Study design
This is an interventional study planning to enroll about 62 participants. You would be randomly assigned to either an aerobic and resistance exercise group or a usual care group.
What's involved
You would have screening, study interventions, and evaluations including blood draws, body composition, fitness tests, and surveys. The exercise group will perform virtual, supervised exercise three times a week for 16 weeks, and have three testing visits. The usual care group will maintain their current exercise levels and have two testing visits.
Compensation
Not stated in the trial record.
Follow-up
Participants will be on the research study for 4 months, with cardiovascular disease risk factors measured at baseline to 4 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05327465

Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy

Recruiting
NAAges 18+InterventionalSupportive care
Dana-Farber Cancer Institute
~62 participants
Updated 2026-07-29 on ClinicalTrials.gov
What's tested:Aerobic and resistance exerciseUsual Care

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Cardiovascular disease risk factors
Measured over baseline to 4 months

Conditions

Androgen Deprivation Therapy
Prostate Cancer
Prostate Cancer Metastatic

Explore related trials

Prostate Carcinoma

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Christina C Dieli-Conwright, PhD, MPH · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute

Who to contact

Christina Dieli-Conwright, PhD, MPH
[email protected]
617-632-3800
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients must meet all criteria to be eligible, including travel to Dana-Farber Cancer Institute (DFCI) to collect research data to address the study question.
Over 18 years old; children under the age of 18 will be excluded due to the rarity of the disease
Histologically diagnosed of localized or metastatic prostate cancer
Have been receiving androgen deprivation therapy (ADT) (i.e., luteinizing hormone-releasing hormone \[LHRH\] agonist/antagonist and/or androgen receptor \[AR\] agonist/antagonist) for at least one month with a plan to continue ADT for at least 4 months at the time of recruitment
Self-identify as Black
Medically cleared to participate in exercise by their referred physician or a certified clinical exercise physiologist
Are without medical conditions that could exacerbate with exercise, such as bone disease (excluding bone metastases) at imminent risk of fracture or uncontrolled cardiopulmonary or metabolic diseases
Speak English and/or Spanish
Currently participate in less than or equal to 60 minutes of moderate or vigorous structured exercise/week
Willing to travel to DFCI for necessary data collection
Ability to communicate and complete written forms in English and/or Spanish

Exclusion

Are not receiving ADT (i.e., LHRH agonist/antagonist and/or AR agonist/antagonist)
Pre-existing medical conditions such as uncontrolled cardiopulmonary disease, or metabolic diseases that could exacerbate with exercise
Are not English or Spanish speaking
Patients with secondary diagnosis (with the exception of basal cell carcinoma)
Participate in more than 60 minutes of moderate or vigorous structured exercise/week
Unable to travel to DFCI for necessary data collection
May not be able to comply with the safety monitoring requirements of the study in the opinion of the investigator.

What this trial measures

  • Cardiovascular disease risk factorsbaseline to 4 months

    Framingham Risk Score, an established comprehensive tool for evaluating the risk of developing cardiovascular disease using blood samples (i.e., low-density lipoprotein-cholesterol \[LDL-C\] or total cholesterol \[TC\], high-density lipoprotein-cholesterol \[HDL-C\]), demographic and medical profiles , and lifestyle behaviors (i.e., age, blood pressure, and diabetic and smoking status). The score ranges from -4 to 36 and the 10-year cardiovascular risk will be calculated accordingly (a higher score indicates a higher risk of cardiovascular disease).